Citigroup
EIDX

Citigroup’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Citigroup’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-87,000
Closed -$11.4M – 7867
2020
Q4 		$11.4M Buy
87,000
+84,103
+2,903% +$7.43M 0.01% 1445
2020
Q3 		$146K Sell
2,897
-106,444
-97% -$4.78M ﹤0.01% 4841
2020
Q2 		$5.21M Buy
109,341
+103,709
+1,841% +$4.82M ﹤0.01% 1820
2020
Q1 		$276K Sell
5,632
-10,058
-64% -$512K ﹤0.01% 4448
2019
Q4 		$900K Buy
15,690
+13,880
+767% +$687K ﹤0.01% 3860
2019
Q3 		$65K Sell
1,810
-2,626
-59% -$103K ﹤0.01% 5967
2019
Q2 		$138K Sell
4,436
-437
-9% -$11.8K ﹤0.01% 5583
2019
Q1 		$114K Buy
4,873
+3,537
+265% +$56.8K ﹤0.01% 5618
2018
Q4 		$18K Sell
1,336
-692
-34% -$8.73K ﹤0.01% 6937
2018
Q3 		$20K Buy
+2,028
New +$33.3K ﹤0.01% 7095

Citigroup's EIDX Position: Q1 2021 in Review

Citigroup sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 87,000 shares — an estimated $11.4M sold.

Citigroup first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $11.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Citigroup reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Citigroup sold 87,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $11.4M.
  • Citigroup first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • Citigroup's Eidos Therapeutics, Inc. Common Stock position peaked at $11.4M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.